Based on a survey of the Arcview Investor Network, the cannabis industry’s largest investor group, nearly two-thirds of investors (64%) are interested in investing in ancillary commercial products. This is three times the level of interest in cannabis dispensaries (21%), which are often perceived as the first point of entry into the cannabis industry. Ancillary companies are a popular investment vehicle because they face less regulatory oversight, have lower barriers to entry, and are easier to scale across state markets than companies which touch the plant.